Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder.

Tytuł:
Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder.
Autorzy:
Arnaldi D; Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa, Italy.; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Chincarini A; National Institute of Nuclear Physics (INFN), Genoa section, Genoa, Italy.
Hu MT; Oxford Parkinson's Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Sonka K; Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Boeve B; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Miyamoto T; Department of Neurology, Dokkyo Medical University Saitama Medical Centre, Saitama, Japan.
Puligheddu M; Sleep Disorder Centre, Department of Medical Sciences and Public Health, University of Cagliari, Italy.
De Cock VC; Department of Sleep and Neurology, Beau Soleil Clinic, and EuroMov Digital Health in Motion, University of Montpellier, Montpellier, France.
Terzaghi M; Unit of Sleep Medicine and Epilepsy, IRCCS Mondino Foundation, Pavia, Italy.; Department of Brain and Behavioural Sciences, University of Pavia, Pavia, Italy.
Plazzi G; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Tachibana N; Division of Sleep Medicine, Kansai Electric Power Medical Research Institute, Osaka, Japan.
Morbelli S; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.; Nuclear Medicine, Department of Health Sciences (DISSAL), University of Genoa, Italy.
Rolinski M; Oxford Parkinson's Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.; Institute of Clinical Neurosciences, University of Bristol, Bristol, UK.
Dusek P; Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Lowe V; Department of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Miyamoto M; Centre of Sleep Medicine, Dokkyo Medical University Hospital, Tochigi, Japan.
Figorilli M; Sleep Disorder Centre, Department of Medical Sciences and Public Health, University of Cagliari, Italy.
Verbizier D; Nuclear Medicine Unit, University hospital of Montpellier, France.
Bossert I; Nuclear Medicine Unit, ICS Maugeri SpA SB IRCCS, Pavia, Italy.
Antelmi E; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.; Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Meli R; Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa, Italy.; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Barber TR; Oxford Parkinson's Disease Centre, Nuffield Department of Clinical Neurosciences, University of Oxford, John Radcliffe Hospital, Oxford, UK.
Trnka J; Institute of Nuclear Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Miyagawa T; Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
Serra A; Nuclear Medicine Unit, Department of Medical Science and Public Health, University of Cagliari, Cagliari, Italy.
Pizza F; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.; IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Bauckneht M; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.; Nuclear Medicine, Department of Health Sciences (DISSAL), University of Genoa, Italy.
Bradley KM; PETIC, University Hospital of Wales, Cardiff, UK.
Zogala D; Institute of Nuclear Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
McGowan DR; Radiation Physics and Protection Department, Churchill Hospital, Oxford, UK.
Jordan L; Department of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Manni R; Unit of Sleep Medicine and Epilepsy, IRCCS Mondino Foundation, Pavia, Italy.
Nobili F; Clinical Neurology, Department of Neuroscience (DINOGMI), University of Genoa, Italy.; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Źródło:
Brain : a journal of neurology [Brain] 2021 Feb 12; Vol. 144 (1), pp. 278-287.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Język:
English
Imprint Name(s):
Publication: Oxford : Oxford University Press
Original Publication: London.
MeSH Terms:
Caudate Nucleus/*diagnostic imaging
Dopamine Plasma Membrane Transport Proteins/*metabolism
Putamen/*diagnostic imaging
REM Sleep Behavior Disorder/*diagnostic imaging
REM Sleep Behavior Disorder/*metabolism
Synucleinopathies/*diagnostic imaging
Synucleinopathies/*metabolism
Aged ; Caudate Nucleus/metabolism ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Putamen/metabolism ; ROC Curve ; Retrospective Studies ; Tomography, Emission-Computed, Single-Photon ; Tropanes
References:
J Psychiatr Res. 1975 Nov;12(3):189-98. (PMID: 1202204)
Sleep Med Rev. 2018 Oct;41:266-274. (PMID: 29784534)
Mov Disord. 2015 Dec;30(14):1967-70. (PMID: 26779608)
Sleep Med. 2021 Mar;79:205-210. (PMID: 32451160)
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):443-50. (PMID: 19838702)
Neurology. 2020 Apr 28;94(17):743-755. (PMID: 32241955)
Neurology. 2004 May 11;62(9):1568-72. (PMID: 15136683)
Neurology. 2017 Apr 18;88(16):1493-1500. (PMID: 28330956)
Mov Disord. 2004 Nov;19(11):1306-12. (PMID: 15390007)
Parkinsonism Relat Disord. 2014 Jan;20(1):99-105. (PMID: 24183678)
Ann Neurol. 2018 May;83(5):1016-1026. (PMID: 29665124)
Neurology. 2017 Jul 4;89(1):88-100. (PMID: 28592453)
Rhinology. 1999 Dec;37(4):145-8. (PMID: 10670026)
Physiol Behav. 1984 Mar;32(3):489-502. (PMID: 6463130)
Neuroimage Clin. 2018 Apr 06;19:130-136. (PMID: 30035010)
Sleep Med Rev. 2019 Feb;43:37-46. (PMID: 30503716)
Mov Disord. 2010 Jan 15;25(1):35-43. (PMID: 20058228)
Stat Med. 1982 Apr-Jun;1(2):121-9. (PMID: 7187087)
Chem Senses. 2006 May;31(4):335-42. (PMID: 16495437)
Mov Disord. 2014 Dec;29(14):1809-15. (PMID: 25381961)
Mov Disord. 2007 Jan;22(1):41-7. (PMID: 17115387)
Mov Disord. 2015 Oct;30(12):1600-11. (PMID: 26474317)
J Nucl Med. 2020 Nov;61(11):1628-1635. (PMID: 32198310)
Mov Disord. 2015 Oct;30(12):1591-601. (PMID: 26474316)
Chem Senses. 1997 Feb;22(1):39-52. (PMID: 9056084)
J Am Geriatr Soc. 2005 Apr;53(4):695-9. (PMID: 15817019)
Clin Transl Sci. 2018 Jan;11(1):63-70. (PMID: 28749580)
Brain. 2019 Mar 1;142(3):744-759. (PMID: 30789229)
Ann Neurol. 2017 Sep;82(3):419-428. (PMID: 28833467)
Grant Information:
MR/L023784/1 United Kingdom MRC_ Medical Research Council; J-0901 United Kingdom PUK_ Parkinson's UK; MC_EX_MR/N50192X/1 United Kingdom MRC_ Medical Research Council; MR/M024962/1 United Kingdom MRC_ Medical Research Council; U01 NS100620 United States NS NINDS NIH HHS
Contributed Indexing:
Keywords: Parkinson’s disease; REM sleep behaviour disorder; SPECT; dementia with Lewy bodies
Substance Nomenclature:
0 (Dopamine Plasma Membrane Transport Proteins)
0 (Tropanes)
155797-99-2 (2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane)
Entry Date(s):
Date Created: 20201221 Date Completed: 20210420 Latest Revision: 20240404
Update Code:
20240404
PubMed Central ID:
PMC8599912
DOI:
10.1093/brain/awaa365
PMID:
33348363
Czasopismo naukowe
This is an international multicentre study aimed at evaluating the combined value of dopaminergic neuroimaging and clinical features in predicting future phenoconversion of idiopathic REM sleep behaviour (iRBD) subjects to overt synucleinopathy. Nine centres sent 123I-FP-CIT-SPECT data of 344 iRBD patients and 256 controls for centralized analysis. 123I-FP-CIT-SPECT images were semiquantified using DaTQUANTTM, obtaining putamen and caudate specific to non-displaceable binding ratios (SBRs). The following clinical variables were also analysed: (i) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale, motor section score; (ii) Mini-Mental State Examination score; (iii) constipation; and (iv) hyposmia. Kaplan-Meier survival analysis was performed to estimate conversion risk. Hazard ratios for each variable were calculated with Cox regression. A generalized logistic regression model was applied to identify the best combination of risk factors. Bayesian classifier was used to identify the baseline features predicting phenoconversion to parkinsonism or dementia. After quality check of the data, 263 iRBD patients (67.6 ± 7.3 years, 229 males) and 243 control subjects (67.2 ± 10.1 years, 110 males) were analysed. Fifty-two (20%) patients developed a synucleinopathy after average follow-up of 2 years. The best combination of risk factors was putamen dopaminergic dysfunction of the most affected hemisphere on imaging, defined as the lower value between either putamina (P < 0.000001), constipation, (P < 0.000001) and age over 70 years (P = 0.0002). Combined features obtained from the generalized logistic regression achieved a hazard ratio of 5.71 (95% confidence interval 2.85-11.43). Bayesian classifier suggested that patients with higher Mini-Mental State Examination score and lower caudate SBR asymmetry were more likely to develop parkinsonism, while patients with the opposite pattern were more likely to develop dementia. This study shows that iRBD patients older than 70 with constipation and reduced nigro-putaminal dopaminergic function are at high risk of short-term phenoconversion to an overt synucleinopathy, providing an effective stratification approach for future neuroprotective trials. Moreover, we provide cut-off values for the significant predictors of phenoconversion to be used in single subjects.
(© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies